Original Report

A modified olanzapine regimen for the prevention of chemotherapy-induced nausea and vomiting


 

Background At Kaiser Permanente Antioch and Walnut Creek Cancer Centers, a modified olanzapine regimen is used to prevent chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC).

Objective To determine if an olanzapine, ondansetron, dexamethasone (OOD) regimen is noninferior to a fosaprepitant, ondansetron, dexamethasone (FOD) regimen in preventing CINV in patients receiving HEC.

Methods This retrospective cohort study compared the rates of CINV in patients who were treated with HEC and received either the OOD or FOD regimen. Electronic medical records were assessed for documented reports of CINV. 148 patients were included in this study.

Results Complete response (CR), defined as no emesis after Cycle 1 of HEC, in patients receiving the OOD regimen was 95.7% in the acute phase, 94.3% in the delayed phase, and 92.9% overall. CR in patients receiving the FOD regimen was 98.7% in the acute phase, 89.7% in the delayed phase, and 89.7% overall. The percentage of patients who had no nausea on the OOD regimen was 87.1 in the acute phase, 75.5 in the delayed phase, and 71.4 overall, compared with 78.2 in the acute phase, 62.8 in the delayed phase, and 62.7 overall in patients on the FOD regimen.

Limitations This study was limited by its retrospective, nonrandomized design, and short follow-up period. This study did not assess adverse effects from the antiemetic regimens.

Conclusions A modified olanzapine regimen is noninferior to a standard fosaprepitant regimen in regard to CR in showing improved control of CINV. In addition, the use of the olanzapine regimen reduces patient exposure to corticosteroids and the risk of associated side effects, and it is significantly more cost effective, compared with the fosaprepitant regimen.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

How to fix clinical trial accrual
MDedge Hematology and Oncology
Cancer-related pain management in clinical oncology
MDedge Hematology and Oncology
Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy
MDedge Hematology and Oncology
NCCN unveils 'Evidence Blocks' to facilitate treatment discussions
MDedge Hematology and Oncology
Dexamethasone reduces radiation therapy–induced pain flare
MDedge Hematology and Oncology
FDA finds long-term clopidogrel does not increase death or cancer risks
MDedge Hematology and Oncology
Survivors of childhood cancers at increased risk for autoimmune diseases
MDedge Hematology and Oncology
Suicide rate high in patients with head and neck cancer
MDedge Hematology and Oncology
ACS: Watchful waiting for some rectal cancers almost ready for ‘prime time’
MDedge Hematology and Oncology
Balancing clinical and supportive care at every step of the disease continuum
MDedge Hematology and Oncology